CASTLE BIOSCIENCES INC (CSTL) Stock News
NASDAQ:CSTL - Nasdaq - US14843C1053 - Common Stock - Currency: USD
CSTL Latest News, Press Relases and Analysis
SciBase has signed a Collaboration and License Agreement with Castle Biosciences to develop diagnostic tests within dermatology and intends to carry out a directed share issue of approximately MSEK 30
/PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of AI-based diagnostic solutions for skin disorders, today announced it has...
Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases
Castle Biosciences, Inc. today announced that it has entered entered into a collaboration and license agreement with SciBase Holding AB. ...
Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases
Initial Development Project Targets Predicting Flares in Patients Diagnosed with Atopic Dermatitis
Castle Biosciences’ Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention
Derek Maetzold, CEO of Castle Biosciences, will participate in a panel discussion alongside other industry leaders during BIO 2025....
Castle Biosciences to Acquire Previse
Castle Biosciences, Inc. (Nasdaq: CSTL) has signed a definitive agreement to acquire Capsulomics, Inc., d/b/a Previse. ...
Castle Biosciences’ Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention
Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards®
New Data at ASCO 2025 Affirms DecisionDx®-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes
Castle will present new data aimed at enhancing the clinical management of patients with cutaneous melanoma and uveal melanoma at ASCO 2025....
New Data at ASCO 2025 Affirms DecisionDx®-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes
Study results show that DecisionDx-Melanoma was associated with a 32% reduction in mortality risk compared to untested patients
Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference
Castle's executive management will present a company overview at the 2025 Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 7:35 am ET...
Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference
Real-World Study Confirms Long-Term Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result
Castle presented new data from the first independent validation of the recently published COOG2.1 study by Harbour et al. at ARVO 2025....
Castle Biosciences Celebrates Skin Cancer Awareness Month
Castle continues its ongoing patient advocacy partnerships and highlights cancer journey to drive education and awareness for Skin Cancer Awareness Month...
Castle Biosciences Celebrates Skin Cancer Awareness Month
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates
Castle Biosciences (CSTL) delivered earnings and revenue surprises of -150% and 9.97%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: BTAI
Castle Biosciences Reports First Quarter 2025 Results
Castle Biosciences, Inc. (Nasdaq: CSTL) today announced its financial results for the first quarter ended March 31, 2025....
Castle Biosciences Reports First Quarter 2025 Results
Castle Biosciences to Acquire Previse
New Data at DDW 2025 Further Demonstrates the TissueCypher® Test's Ability to Identify Patients at Increased Risk for Developing Esophageal Cancer
Castle Biosciences will share new data on its TissueCypher test for patients with Barrett’s esophagus at DDW 2025....
New Data at DDW 2025 Further Demonstrates the TissueCypher® Test's Ability to Identify Patients at Increased Risk for Developing Esophageal Cancer
New Study Shows Castle Biosciences’ DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity
Castle announced the publication of a new study demonstrating DecisionDx-Melanoma outperforms AJCC staging and the CP-GEP test....
DecisionDx®-Melanoma Test Ordered More Than 200,000 Times for Patients Diagnosed with Cutaneous Melanoma
Castle announces its achievement of surpassing a significant milestone of 200,000 DecisionDx-Melanoma clinical test orders....
DecisionDx®-Melanoma Test Ordered More Than 200,000 Times for Patients Diagnosed with Cutaneous Melanoma
New Data at AACR Annual Meeting Highlights Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis
Castle Biosciences will share new data intended to improve the care of patients with cutaneous and uveal melanoma at the AACR Annual Meeting 2025....
New Data at AACR Annual Meeting Highlights Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis
Castle Biosciences to Release First Quarter 2025 Financial Results and Host Conference Call on Monday, May 5, 2025
Castle will release its financial results for the first quarter ended March 31, 2025, after the close of market on Monday, May 5, 2025....
Castle Biosciences to Release First Quarter 2025 Financial Results and Host Conference Call on Monday, May 5, 2025
Castle Biosciences Strengthens Commitment to Esophageal Cancer Awareness Through Collaborative Partnerships
Castle is supporting key educational programs and initiatives throughout April in recognition of Esophageal Cancer Awareness Month....
Castle Biosciences Strengthens Commitment to Esophageal Cancer Awareness Through Collaborative Partnerships
Castle Biosciences Honored with a Top Workplaces USA Award for Fourth Consecutive Year
Castle announces 4th Top Workplaces USA win, ranking 30th of 358 U.S. companies with 500-999 employees...
Castle Biosciences Honored with a Top Workplaces USA Award for Fourth Consecutive Year
Publication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy with Information from Castle Biosciences’ DecisionDx®-Melanoma Test
Castle announced the recent publication of prospective data demonstrating the significant impact of DecisionDx-Melanoma on SLNB decision-making....
Castle Biosciences to Present New Data at EADO Supporting the Clinical Value of the DecisionDx®-Melanoma Test in Guiding Risk-Aligned Management of Patients with Melanoma
Castle will present data on DecisionDx-Melanoma at the 11th World Congress of Melanoma and 21st European Association of Dermato-Oncology (EADO) Congress....